-
2024-510810-33-00
5
2024-10-14
Severe eosinophilic asthma
-
2024-513724-42-00
10
Medulloblastoma
-
2024-516734-35-00
5
triple-negative early breast cancer
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523990-40-00
5
Newly diagnosed Multiple Myeloma in patients eligible for stem cell tr
-
2025-524289-56-00
6
Asthma
-
2025-522484-15-00
5
2026-04-27
ER+/HER2- early breast cancer
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2025-520997-21-00
4
2026-05-08
Psoriatic arthritis
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-521456-35-00
4
2026-04-13
Mild to moderate asthma
-
2025-523141-10-00
4
2026-03-20
Active Psoriatic Arthritis
-
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
-
2025-521059-21-00
4
2025-11-25
Radiographic axial spondyloarthritis (as known as ankylosing spondylit
-
2024-514695-41-00
5
2025-10-17
Ulcerative Colitis
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2022-503142-41-00
5
2024-05-06
Mucopolysaccharidosis type II
-
2022-501944-14-00
5
2023-10-02
Patients after gastrectomy (total and partial)
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2024-510990-21-00
10
2022-11-11
Mucopolysaccharidosis Type II [MPS II]